FDA Approves Tildrakizumab for Treatment of Active Psoriatic Arthritis

The U.S. Food and Drug Administration (FDA) has approved tildrakizumab-asmn (ILUMYA) for the treatment of adults with active psoriatic arthritis (PsA). This expands the interleukin (IL)-23 inhibitor's indications beyond moderate-to-severe plaque psoriasis, offering a new targeted option for patients with active joint disease.